Andere talen Takeda Pharmaceutical Company Limited

Aandelen

4502

JP3463000004

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4.089 ^JPY	-0,02%		+0,49%	+0,86%

26/04	Hutchmed noteert positief advies CHMP voor goedkeuring fruiquintinib	AN
26/04	Comité van het Europees Geneesmiddelenbureau steunt goedkeuring van Fruquintinib van Takeda voor de behandeling van colorectale kanker	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	26/04
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26/04
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	26/04
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26/04
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26/04
Takeda investit cinq millions dans le renouvelable à Neuchâtel	23/04
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22/04
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22/04
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy	22/04
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9	19/04
Sector Update: Health Care Stocks Steady Pre-Bell Friday	19/04
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	19/04
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease	19/04
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	18/04
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	16/04
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food	08/04
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	01/04
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	27/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Takeda Pharmaceutical Company Limited

Aandelen

4502

JP3463000004

Andere talen

Filters